Following the completion of the transaction, Skeletal Cell Therapy's manufacturing infrastructure and production operating teams have become a part of Catalent's Cell and Gene Therapy division.

Under the terms, Catalent acquires Skeletal Cell Therapy for $14.2 million. The transaction generates net proceeds of approximately $7.1 million for Bone Therapeutics. The transaction excludes any intellectual property rights.

Bone Therapeutics and Catalent are currently involved in some supply agreements, and the acquired manufacturing entity will continue to service the production of ALLOB, Bone Therapeutics' allogenic cell therapy product, for Bone Therapeutics and its partners.

Bone Therapeutics will focus its strategy on the development of products from its differentiated mesenchymal stromal cell platform of cell and gene therapeutic targets for orthopedics and other indications.

Catalent to support AstraZeneca COVID-19 vaccine manufacturing
Catalent and AstraZeneca have signed an agreement to expand manufacturing support for an adenovirus vector-based COVID-19 vaccine from the University...

Eurofins DiscoverX expands program with Catalent
Eurofins DiscoverX has expanded its contract research organization certification program for bioassays with Catalent Biologics as the North American provider.

Catalent to provide fill-finish for Moderna's COVID-19 vaccine
Catalent will collaborate with Moderna for large-scale commercial fill-finish manufacturing of Moderna's messenger RNA-based COVID-19 vaccine candidate,...